Arrowhead Pharmaceuticals has announced that Janssen has started dosing in a REEF-1 Phase IIb study of different combination regimens, including JNJ-3989, and/or JNJ-6379, and a nucleos(t)ide analogue (NA) to treat patients with chronic hepatitis B virus (HBV) infection.

Janssen paid Arrowhead $25m in milestone payment for the study.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The liver-targeted investigational antiviral therapeutic JNJ-3989 is designed as a subcutaneous infusion to treat chronic HBV infection through the ribonucleic acid interference (RNAi) mechanism.

The investigational drug is an orally administered capsid assembly modulator of the class that forms normal capsid structures (CAM-N).

Last October, Arrowhead signed a collaboration agreement with Janssen to develop and commercialise JNJ-3989, which was then ARO-HBV.

“We are thrilled that JNJ-3989, formerly ARO-HBV, is one of the agents being investigated.”

Arrowhead president and CEO Christopher Anzalone said: “Patients with chronic hepatitis B infection are in need of new medicines that improve functional cure rates with finite treatment regimens.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We are thrilled that JNJ-3989, formerly ARO-HBV, is one of the agents being investigated in Janssen’s REEF-1 triple combination Phase IIb study.”

The Phase IIb, multi-centre, double-blind, randomised REEF-1 trial will evaluate the safety and efficacy of the combination regimens and placebo in patients identified with chronic HBV infection.

The study is intended to include around 450 patients who will be randomised to receive treatment for up to 48 weeks.

HBV infects the liver and causes infectious hepatitis. The disease spreads from person to person through sharing needles or syringes, sexual intercourse and from mother to baby during birth.

According to the World Health Organization (WHO), more than 292 million people worldwide have hepatitis B.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact